FLAG-Ida combined with gemtuzumab ozogamicin (GO) improves event free survival in younger patients with newly diagnosed acute myeloid leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 Trial
Russell, N. H. Wilhelm-Benartzi, C. Knapper, S. Batten, L. M. Canham, J. Hinson, E. L. Overgaard, U. M. Gilkes, A. Othman, J. Potter, N.
Russell, N. H.
Wilhelm-Benartzi, C.
Knapper, S.
Batten, L. M.
Canham, J.
Hinson, E. L.
Overgaard, U. M.
Gilkes, A.
Othman, J.
Potter, N.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Russell NH, Wilhelm-Benartzi C, Knapper S, Batten LM, Canham J, Hinson EL, et al. FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial. Blood. 2022 Nov;140. PubMed PMID: WOS:000893223200218.